AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$GRCE

Opaleye Management Inc. purchased $32K of GRCE (indirect holdings)

Opaleye Management Inc. purchased 15,089 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at $2.10 across 2 trades over 2026-09-21 to 2026-09-23.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Sep 23, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRCE
Neutral
medium confidence
Mentioned
$GRCE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The filing provides the first public disclosure of this insider transaction.

02

Market read

Minor relevance; likely no immediate market move.

03

What to watch

Potential upcoming clinical data not disclosed.

Relevance 4/10Novelty 4/10Timing: Filed after market close on 2026-09-23

Background

Grace Therapeutics is a clinical-stage biotech; insider purchases are regularly reported via Form 4.

Company-level read

Ticker impact

$GRCENeutralMedium confidence
Context

Form 4 shows Opaleye Management bought 15,089 shares of Grace Therapeutics at $2.10, totaling $31.7K.

Expected impact

Minimal short-term movement expected.

Evidence & confidence

Purchase size is modest relative to float; no material change in ownership.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to Grace Therapeutics shareholders.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio adjustment, not a bullish signal.

Key entities

  • Company
    Grace Therapeutics, Inc.

    Biotech issuer of the shares purchased.

  • Investor
    Opaleye Management Inc.

    Entity reporting the insider purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics Announces First Quarter 2027 Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min